Abstract
The microtubule (MT) represents a highly validated target for therapy. Insights into the complex nature of the dynamic microtubule physiology will provide the basis for developing novel microtubule targeting agents with enhanced efficacy and minimised toxicity. In this article, with an emphasis on translational applications, we have summarised relevant aspects of tubulin physiology in the context of developing MT binding agents as therapeutic agents. Case studies were included to illustrate therapeutic developments in prostate cancer and current strategies to discover novel agents or targets for therapy.
Keywords: Microtubule (MT), microtubule associated proteins (MAPs), microtubule targeting agents (MTAs), chemotherapy, tubulin heterodimers, polymerases, angiogenesis, neutropenia, p21-activated kinase 6 (PAK6), prostate cancer
Current Pharmaceutical Design
Title:Approaches for Developing Novel Microtubule Targeting Agents (MTAs) for Therapeutic Exploitation
Volume: 18 Issue: 19
Author(s): Aswini Krishnan, James Wilson and Hing Y. Leung
Affiliation:
Keywords: Microtubule (MT), microtubule associated proteins (MAPs), microtubule targeting agents (MTAs), chemotherapy, tubulin heterodimers, polymerases, angiogenesis, neutropenia, p21-activated kinase 6 (PAK6), prostate cancer
Abstract: The microtubule (MT) represents a highly validated target for therapy. Insights into the complex nature of the dynamic microtubule physiology will provide the basis for developing novel microtubule targeting agents with enhanced efficacy and minimised toxicity. In this article, with an emphasis on translational applications, we have summarised relevant aspects of tubulin physiology in the context of developing MT binding agents as therapeutic agents. Case studies were included to illustrate therapeutic developments in prostate cancer and current strategies to discover novel agents or targets for therapy.
Export Options
About this article
Cite this article as:
Krishnan Aswini, Wilson James and Y. Leung Hing, Approaches for Developing Novel Microtubule Targeting Agents (MTAs) for Therapeutic Exploitation, Current Pharmaceutical Design 2012; 18 (19) . https://dx.doi.org/10.2174/138161212800626111
DOI https://dx.doi.org/10.2174/138161212800626111 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Combination of Hypoxia and RNA-Interference Targeting VEGF Induces Apoptosis in Hepatoma Cells Via Autocrine Mechanisms
Current Pharmaceutical Biotechnology Imiquimod 5% Cream Use in Dermatology, Side Effects and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Nonsense-Mediated mRNA Decay: A Comparative Analysis of Different Species
Current Genomics Delivery Systems for RNA Interference Therapy: Current Technologies and Limitations
Current Gene Therapy (Iso)Flav(an)ones, Chalcones, Catechins, and Theaflavins as Anticarcinogens: Mechanisms, Anti-Multidrug Resistance and QSAR Studies
Current Medicinal Chemistry Intracellular Delivery of Potential Therapeutic Genes: Prospects in Cancer Gene Therapy
Current Gene Therapy Restoring TRAIL Induced Apoptosis Using Naturopathy. Hercules Joins Hand with Nature to Triumph Over Lernaean Hydra
Current Genomics Platinum-Intercalator Conjugates: From DNA-Targeted Cisplatin Derivatives to Adenine Binding Complexes as Potential Modulators of Gene Regulation
Current Topics in Medicinal Chemistry Ligand-modified Biopolymeric Nanoparticles as Efficient Tools for Targeted Cancer Therapy
Current Pharmaceutical Design Progress Toward Vector Design for Hematopoietic Stem Cell Gene Therapy
Current Gene Therapy The Gene Expression Profiles of Medulloblastoma Cell Lines Resistant to Preactivated Cyclophosphamide
Current Cancer Drug Targets Accessing the Blood-Brain Barrier to Treat Brain Disorders
Current Nanomedicine Fibrates in the Chemical Action of Daunorubicin
Current Cancer Drug Targets Therapeutic Targeting of Chemokines with Monoclonal Antibodies
Current Immunology Reviews (Discontinued) Immune Mechanism, Aging, Season and Diseases: Modulatory Role of Melatonin
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Emerging Role of Vascular Endothelial Growth Factor (VEGF) in Vascular Homeostasis: Lessons from Recent Trials with Anti-VEGF Drugs
Current Vascular Pharmacology NFAT Gene Family in Inflammation and Cancer
Current Molecular Medicine PEGylated Liposomal Vancomycin: A Glimmer of Hope for Improving Treatment Outcomes in MRSA Pneumonia
Recent Patents on Anti-Infective Drug Discovery Recent Advances in Cancer Drug Development: Targeting Induced Myeloid Cell Leukemia-1 (Mcl-1) Differentiation Protein
Current Medicinal Chemistry Subject Index To Volume 13
Current Medicinal Chemistry